Medicine and Dentistry
Neoadjuvant Chemotherapy
100%
Recurrent Disease
60%
Esophageal Cancer
55%
Esophageal Adenocarcinoma
55%
Survival
55%
Surgery
54%
Famotidine
50%
Esophagus
50%
PET-MRI
50%
Fluorodeoxyglucose F 18
50%
Surgical Margin
50%
Experience
50%
Adenocarcinoma
50%
Lymph Node
50%
Neoplasm
32%
PET-CT
32%
Computed Tomography
25%
Patient
17%
Odds Ratio
15%
Metastatic Carcinoma
10%
Primary Tumor
10%
Tumor Regression
9%
Inpatient
7%
Nuclear Medicine Physician
7%
Consensus
7%
Hazard Ratio
7%
Bootstrapping
5%
Tumor Differentiation
5%
Differentiation
5%
Progressive Disease
5%
Analysis
5%
Recurrence Risk
5%
Lymphovascular Invasion
5%
Diagnosis
5%
Biochemistry, Genetics and Molecular Biology
Positron Emission Tomography
50%
Staging
50%
Experience
50%
Magnetic Resonance Imaging
50%
Positron Emission Tomography-Computed Tomography
32%
Consensus
7%
Pharmacology, Toxicology and Pharmaceutical Science
Adenocarcinoma
50%
Chemotherapy
50%
Neoplasm
20%
Recurrent Disease
10%
Lymph Vessel Metastasis
5%
Esophagus Cancer
5%
Survival
5%
Diseases
5%
Esophageal Adenocarcinoma
5%
Recurrence Risk
5%
